Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208261 | 0.86 | LMNA (0.45) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL2034671 | 0.81 | LMNA (0.51) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL9339167 | 0.79 | LMNA (0.50) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL14406916 | 0.79 | LMNA (0.50) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL28192075 | 0.79 | LMNA (0.50) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL23562090 | 0.77 | LMNA (0.62) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL12890137 | 0.77 | LMNA (0.48) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL1255539 | 0.77 | LMNA (0.62) | LMNAKDM4EGAACA1CA2 | |
| SCHEMBL28704033 | 0.76 | CA1 (0.76) | KDM4ECA1CA2CA12CA7 | |
| SCHEMBL3174187 | 0.75 | IDH1 (0.50) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491146-B2 | Therapeutic methods and combinations | SHAM YUK YIN (US) | 2022-11-08 | — | — | US | disclosed |
| US-20180369217-A1 | THERAPEUTIC METHODS AND COMBINATIONS | SHAM YUK YIN (US) | 2018-12-27 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-1546133-B1 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7138525-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6869966-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369217-A1 | THERAPEUTIC METHODS AND COMBINATIONS | TPMT, TOP1, TOP2A | LMNA 4573/4885KDM4E 4544/4885GAA 855/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | LMNA 3672/4885KDM4E 2088/4885GAA 4839/4885 |
| US-11491146-B2 | Therapeutic methods and combinations | TPMT, TOP1, TOP2A | LMNA 4573/4885KDM4E 4544/4885GAA 855/4885 |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | LMNA 1221/4885KDM4E 3641/4885GAA 1524/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | LMNA 1221/4885KDM4E 3641/4885GAA 1524/4885 |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | NPY1R, NPY2R, NPY4R | LMNA 2527/4885KDM4E 2556/4885GAA 1984/4885 |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | GPR119, NPY4R, NPY1R | LMNA 3298/4885KDM4E 1692/4885GAA 1691/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | LMNA 3866/4885KDM4E 2711/4885GAA 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.